# US 2026/0263636 A1 · Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263636 A1
- Document ID: US20260263636A1
- Status: Published application
- Kind: A1
- Application number: 19/132,765
- Filed: 2023-11-23
- Published: 2026-09-10
- Earliest claimed: 2022-11-24
- Assignees: ProQR Therapeutics, Inc.
- Applicants: ProQR Therapeutics, Inc.
- Inventors: Marko POTMAN; Aliye Seda YILMAZ-ELIS; Aron KOS
- Web page: https://patentgrep.com/patent/US20260263636A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/1709: {from mammals}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/78: for Pseudomonas
- C12N 15/86: Viral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2310/11: Antisense
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/334: Modified C
- C12N 2310/335: Modified T or U
- C12N 2310/351: Conjugate
- C12N 2310/3533: Halogen
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The disclosure relates to the field of diseases caused by iron overload, such as homeostatic iron regulator protein (HFE) hemochromatosis. The disclosure provides oligonucleotides for RNA editing technology in targeting and deaminating the c.845G>A nucleotide in transcripts of the p.Cys282Tyr (C282Y) mutant human HFE gene to reduce iron overload, especially in the liver.

## Claims

### Claim 1

An RNA editing oligonucleotide (EON) capable of forming a double-stranded complex with a region of an endogenous human HFE transcript molecule in a cell, wherein the region of the HFE transcript molecule comprises a target adenosine, and wherein the double-stranded complex can recruit an endogenous ADAR enzyme to deaminate the target adenosine into an inosine, thereby editing the HFE transcript molecule.

### Claim 2 (depends on 1)

An EON according to claim 1, wherein the HFE transcript molecule is a pre-mRNA or an mRNA molecule.

### Claim 3 (depends on 1, 2)

An EON according to claim 1 or 2, wherein the cell is a human liver cell, preferably a hepatocyte.

### Claim 4 (depends on 1, 2, 3)

An EON according to any one of claims 1 to 3, wherein the target adenosine is a c.845G>A mutation in the human HFE gene.

### Claim 5 (depends on 1, 2, 3, 4)

An EON according to any one of claims 1 to 4, wherein the EON comprises or consists of the nucleotide sequence of any one of the EON sequences of SEQ ID NO:1 to 51 and 66 to 164.

### Claim 6 (depends on 1, 2, 3, 4, 5)

An EON according to any one of claims 1 to 5, wherein at least one nucleotide comprises one or more non-naturally occurring chemical modifications, or one or more additional non-naturally occurring chemical modifications, in the ribose, linkage, or base moiety, with the proviso that the orphan nucleotide, which is the nucleotide in the EON that is directly opposite the target adenosine, is not a cytidine comprising a 2′-OMe ribose substitution.

### Claim 7 (depends on 6)

An EON according to claim 6, wherein the orphan nucleotide is a cytidine analog, preferably a deoxynucleotide comprising a 6-amino-5-nitro-3-yl-2(1H)-pyridone nucleobase.

### Claim 8 (depends on 6)

An EON according to claim 6, wherein the orphan nucleotide is a uridine analog, preferably a deoxynucleotide comprising an iso-uracil nucleobase.

### Claim 9 (depends on 6, 7, 8)

An EON according to any one of claims 6 to 8, wherein the one or more additional modifications in the linkage moiety is each independently selected from a phosphorothioate (PS), phosphonoacetate, phosphorodithioate, methylphosphonate (MP), sulfonylphosphoramidate, or PNdmi internucleotide linkage.

### Claim 10 (depends on 6, 7, 8, 9)

EON according to any one of claims 6 to 9, wherein the one or more additional modifications in the ribose moiety is a mono- or di-substitution at the 2′, 3′ and/or 5′ position of the ribose, each independently selected from the group consisting of:
—OH;
—F;
substituted or unsubstituted, linear or branched lower (C1-C10) alkyl, alkenyl, alkynyl, alkaryl, allyl, or aralkyl, that may be interrupted by one or more heteroatoms;
—O-, S-, or N-alkyl;
—O-, S-, or N-alkenyl;
—O-, S-, or N-alkynyl;
—O-, S-, or N-allyl;
—O-alkyl-O-alkyl;
-methoxy;
-aminopropoxy;
-methoxyethoxy;
-dimethylamino oxyethoxy; and
-dimethylaminoethoxyethoxy.

### Claim 11 (depends on 1, 2, 3, 4, 5)

A vector, preferably a viral vector, more preferably an adeno-associated virus (AAV) vector, comprising a nucleic acid molecule encoding an EON according to any one of claims 1 to 5.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A Lipid Nanoparticle (LNP) formulation comprising an EON according to any one of claims 1 to 10.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A pharmaceutical composition comprising an EON according to any one of claims 1 to 10, a vector according to claim 11, or an LNP formulation according to claim 12; and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

An EON according to claim 1 to 10, a vector according to claim 11, an LNP formulation according to claim 12, or a pharmaceutical composition according to claim 13, for use in the treatment of homeostatic iron regulator protein (HFE) hemochromatosis.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

Use of an EON according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment of homeostatic iron regulator protein (HFE) hemochromatosis.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of editing a HFE polynucleotide, the method comprising contacting the HFE polynucleotide with an EON according to any one of claims 1 to 10, thereby editing the HFE polynucleotide.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating homeostatic iron regulator protein (HFE) hemochromatosis in a patient in need thereof, the method comprising contacting a HFE polynucleotide in a cell of the subject with an EON according to any one of claims 1 to 10, thereby treating the patient.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating HFE hemochromatosis, the method comprising administering to a patient in need thereof a therapeutically effective amount of an EON according to any one of claims 1 to 10, a vector according to claim 11, an LNP formulation according to claim 12, or a pharmaceutical composition according to claim 13.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for the deamination of a target adenosine in an HFE pre-mRNA or mRNA molecule in a cell, the method comprising the steps of:
(i) providing the cell with an EON according to any one of claims 1 to 10;
(ii) allowing uptake by the cell of the EON;
(iii) allowing annealing of the EON to the HFE pre-mRNA or mRNA molecule;
(iv) allowing an endogenous ADAR enzyme to deaminate the target adenosine in the target RNA molecule to an inosine; and optionally
(v) identifying the presence of the inosine in the target RNA molecule.

### Claim 20 (depends on 16, 17, 18, 19)

A method according to any one of claims 16 to 19, wherein the target adenosine is the c.845G>A mutation in the HFE pre-mRNA or mRNA molecule.

### Claim 21 (depends on 19, 20)

A method according to claim 19 or 20, wherein step (v) comprises:
a) determining the sequence of the HFE pre-mRNA or mRNA molecule;
b) assessing the presence of a wild-type HFE protein; or
c) using a functional read-out, preferably assessing a serum or plasma ferritin concentration, or a serum transferrin saturation percentage.
